Condition: Colorectal Cancer Metastatic · Sponsor: National Cancer Institute, Naples
The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long progression free survival (PFS) in first line treatment, might benefit from a personalized approach, with less intensive treatment with regorafenib as part of a continuum-of-care strategy aimed at ensuring quality of life and extending survival.
This description comes directly from the study's public registry record.
Antonio Avallone, MD · 003908117770357 · a.avallone@istitutotumori.na.it
Always discuss trial participation with your own doctor first.
| Istituto Nazionale Tumori | "Fondazione Pascale" | Naples, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07213570